Kairos Pharma, LTD. (KAPA) stock
KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
$0.44+0.04 (+10.08%)
Close on Nov 18, 2026Market cap $1.64MP/E –Yield –
Kairos Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Kairos Pharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$4.11M. For fiscal 2025 it was -$3.44M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.44M | – |
| FY2024 | Dec 31, 2024 | -$3.96M | -4982.7% |
| FY2023 | Dec 31, 2023 | $81.00K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$979.00K | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.04M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$838.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$805.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$714.00K | -2083.3% |
| Q4 FY2024 | Dec 31, 2024 | -$1.80M | -2831.8% |
| Q3 FY2024 | Sep 30, 2024 | -$2.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$168.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $36.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $66.00K | – |
See a number that looks wrong?